Mycosis Fungoides (Cutaneous T-Cell Lymphoma)

A mushroom-shaped tumour, the look that named the disease in 1806
A mushroom-shaped tumour, the look that named the disease in 1806
T lymphocytes, the immune cells that turn cancerous in MF
T lymphocytes, the immune cells that turn cancerous in MF

Table of Contents

  1. Overview and Epidemiology
  2. Pathophysiology and Immunophenotype
  3. Clinical Stages (TNMB Staging)
  4. Diagnosis
  5. Treatment: Skin-Directed Therapies (Early Stage)
  6. Treatment: Systemic Therapies (Advanced Disease)
  7. Prognosis
  8. Quality of Life and Patient Guidance
  9. Key Research Papers
  10. Featured Videos
  11. Connections

Overview and Epidemiology

Mycosis fungoides (MF) is the most common primary cutaneous lymphoma, accounting for approximately 50% of all cutaneous lymphomas. Despite its alarming name — coined by French dermatologist Jean-Louis-Marc Alibert in 1806 after observing mushroom-shaped skin tumors — the disease follows a surprisingly indolent course in most patients, progressing over years to decades rather than months.

MF belongs to the broader category of cutaneous T-cell lymphomas (CTCL), a group of non-Hodgkin lymphomas arising from skin-homing T lymphocytes. The malignant cells are epidermotropic CD4+ T cells — they have an abnormal drive to enter and accumulate within the outer layers of the skin.

Key epidemiological facts:

Back to Table of Contents

Pathophysiology and Immunophenotype

The hallmark of MF is the clonal proliferation of mature, post-thymic CD4+ CD45RO+ memory T cells that have acquired an abnormal drive to home to the epidermis (epidermotropism). In normal immunity, these memory T cells patrol skin tissue; in MF, a clone of these cells accumulates, evades immune surveillance, and eventually transforms into frank lymphoma.

Immunophenotypic profile:

Clonal T-cell receptor (TCR) gene rearrangement is detectable by polymerase chain reaction (PCR) in involved skin and, in advanced disease, in peripheral blood. Identifying the same clone in both skin and blood is central to diagnosing Sézary syndrome. Clonality alone does not establish malignancy — benign conditions can show oligoclonal or even apparently clonal expansions — but TCR clonality in the appropriate clinical and histological context strongly supports the diagnosis of MF.

The precise molecular initiating event is unknown. Candidate pathways include chronic antigen stimulation, JAK-STAT signaling dysregulation, loss of tumor suppressor function (CDKN2A deletion is common), and epigenetic silencing. Transformation to large-cell lymphoma (CD30+ or CD30–) can occur in advanced disease and carries a worse prognosis.

Back to Table of Contents

Clinical Stages (TNMB Staging)

MF is staged using the TNMB system — Tumor extent in skin (T), lymph Node involvement (N), visceral organ involvement (M), and Blood involvement (B). Understanding the clinical appearance at each stage is critical because early MF is notoriously difficult to distinguish from common benign skin conditions.

Patch Stage (Stage IA / IB)

In the International Society for Cutaneous Lymphomas / European Organization for Research and Treatment of Cancer (ISCL/EORTC) staging used in the National Cancer Institute's summary, stage IA means patches, papules or plaques covering less than 10% of the skin, and stage IB means they cover 10% or more, with no abnormal lymph nodes and no organ involvement.

Patches are flat, subtle, scaly erythematous lesions that are frequently misdiagnosed for years as eczema, psoriasis, tinea corporis, or contact dermatitis. Distinguishing features that point toward MF include:

Most patients remain at the patch stage for many years to decades. Stage IA disease (patches covering less than 10% of body surface area) has a near-normal life expectancy with appropriate skin-directed treatment.

Plaque Stage (Stage IA / IB) and Stage IIA (Abnormal Lymph Nodes)

Plaques are thicker, raised, indurated lesions that develop superimposed on, or in place of, existing patches. They may be more intensely erythematous, more pruritic, and show more obvious scaling. In the staging table, plaques count the same way as patches: under 10% of the skin is stage IA and 10% or more is stage IB. Stage IIA is the same patch or plaque picture plus clinically abnormal lymph nodes. At stage IIA, lymph nodes may be palpably enlarged (reactive adenopathy or early involvement), but lymph node biopsy shows only dermatopathic changes without frank lymphomatous involvement.

Tumor Stage (Stage IIB) and Erythroderma (Stage III)

The tumor stage is defined by the emergence of raised, nodular tumors — the "mushroom-shaped projections" that gave the disease its name when Alibert first described it in 1806. One or more tumors of 1 cm or more across define stage IIB. Tumors may ulcerate and become secondarily infected. Prognosis worsens significantly at this stage. Stage III describes diffuse redness of the skin (erythroderma) covering 80% or more of the body surface, without high blood involvement.

Sézary Syndrome — Erythrodermic / Leukemic Variant (Stage IVA1)

Sézary syndrome (SS) is the leukemic variant of CTCL and represents the most severe form of the disease. In the staging table, a high blood count of Sézary cells (B2) places the disease at stage IVA1, whatever the skin stage; stage IVA2 means lymph nodes taken over by lymphoma (N3). Diagnostic criteria require the triad of:

Additional features include severe, debilitating pruritus; fissuring of the palms and soles; ectropion (eyelid eversion); and total alopecia. Sézary syndrome carries a median survival of 2–4 years from diagnosis, making it the most challenging CTCL to manage.

Visceral Stage (Stage IVB)

Stage IVB involves spread to visceral organs — liver, lung, spleen, or bone marrow. This stage carries the worst prognosis and requires systemic chemotherapy approaches, with consideration of allogeneic stem cell transplantation in eligible patients.

Back to Table of Contents

Diagnosis

Diagnosis of MF is notoriously challenging and requires integration of clinical, histopathological, immunophenotypic, and molecular data. No single finding is diagnostic; the diagnosis is established by the overall pattern.

Skin Biopsy

Multiple biopsies from different lesions are usually taken, because a single biopsy has limited sensitivity, and histological findings vary across lesions and over time. Key histological features include:

Immunohistochemistry (IHC)

IHC staining of biopsy material confirms the T-cell lineage and detects antigen loss: CD3+, CD4+, and importantly CD7– (loss) and variable CD5 loss. CD8+ variants exist but are uncommon.

T-Cell Receptor Gene Rearrangement (TCR PCR)

Polymerase chain reaction amplification of the TCR gamma or beta gene detects a clonal T-cell population in skin and peripheral blood. Identical clones in both skin and blood support a diagnosis of Sézary syndrome. Clonality analysis is interpreted alongside clinical and histological findings.

Blood Studies

Staging Imaging

Computed tomography (CT) scan of chest, abdomen, and pelvis (or positron emission tomography/computed tomography (PET-CT) in advanced disease) assesses lymph node and visceral involvement for accurate TNMB staging. Lymph node biopsy is performed when nodes are enlarged to distinguish reactive (dermatopathic) from malignant involvement.

Back to Table of Contents

Treatment: Skin-Directed Therapies (Early Stage)

For patients with stage IA and IB disease (patch and thin plaque stage), the standard approach is skin-directed therapy aimed at controlling symptoms and preventing progression, rather than cure. These treatments are applied to the skin and minimize systemic side effects.

Topical Corticosteroids

High-potency topical steroids are often the first-line treatment for limited patch-stage disease. They reduce inflammation and pruritus and can produce partial or complete remission of individual lesions. Long-term use carries the standard risks of topical steroid atrophy, particularly problematic given the thin skin already characteristic of poikilodermatous patches.

Topical Mechlorethamine (Nitrogen Mustard)

Mechlorethamine gel is a U.S. Food and Drug Administration-approved topical alkylating agent. Its label covers stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have already received skin-directed therapy. It is applied daily to affected skin. In the 260-patient trial behind the gel (Lessin et al., 2013), 58.5% of patients on the gel responded by the main lesion score (Composite Assessment of Index Lesion Severity) and 46.9% by a whole-body score (Modified Severity-Weighted Assessment Tool). The main side effect is skin irritation and contact hypersensitivity; about 20% of patients on the gel left the trial because of drug-related skin irritation. Previously available only as compounded ointments, the U.S. Food and Drug Administration-approved 0.02% gel formulation standardized dosing.

Phototherapy

Total Skin Electron Beam Therapy (TSEBT)

TSEBT delivers low-energy electrons to the entire skin surface. Electrons penetrate only a few millimeters — deep enough to treat MF in the dermis and epidermis, but too shallow to cause significant internal organ exposure. It is highly effective for extensive patch and plaque disease and for early tumor-stage disease. TSEBT is available only at specialized academic centers with the required equipment and physics expertise. Responses are often durable, but MF commonly relapses after 2–3 years, and repeat courses are limited by cumulative skin toxicity.

Back to Table of Contents

Treatment: Systemic Therapies (Advanced Disease)

Advanced-stage MF (tumor stage, erythrodermic, Sézary syndrome, or visceral involvement) requires systemic therapy. Several agents are specifically U.S. Food and Drug Administration-approved for MF/CTCL; others are used off-label or in clinical trials. Conventional cytotoxic chemotherapy is generally not used in early lines because it produces transient responses without survival benefit and causes significant immunosuppression.

Bexarotene

Bexarotene is an oral retinoid X receptor (RXR) agonist that modulates T-cell differentiation and proliferation. U.S. Food and Drug Administration-approved for CTCL, it achieves approximately 45% overall response in previously treated patients. The most significant and nearly universal side effect is severe hypertriglyceridemia (high blood fats). In the label's 300 mg/m²/day group, 60% of patients were given lipid-lowering drugs, and atorvastatin was used in 48%. The label warns against combining bexarotene with gemfibrozil, because gemfibrozil raises the level of bexarotene in the blood. The label states that bexarotene induces (central) hypothyroidism in about half of all patients treated: thyroid-stimulating hormone (TSH) fell in about 60% and total thyroxine (T4) in about 45%, and 37% received thyroid hormone replacement. Bexarotene is a retinoid that causes birth defects; the label states it must not be given to a pregnant woman, and because it may weaken hormonal contraceptives, the label points to non-hormonal contraception.

Vorinostat

Vorinostat was the first histone deacetylase (HDAC) inhibitor approved by the U.S. Food and Drug Administration (FDA) (2006) for the treatment of CTCL in patients with progressive, persistent, or recurrent disease. It is taken orally. HDAC inhibitors work through epigenetic modification — they prevent the removal of acetyl groups from histone proteins, allowing genes involved in cell cycle arrest and apoptosis to remain accessible. Response rates in refractory CTCL are approximately 24–30%. Key side effects include fatigue, gastrointestinal symptoms, thrombocytopenia, and pulmonary embolism risk (requires monitoring).

Romidepsin

Romidepsin is an intravenous HDAC inhibitor (cyclic depsipeptide class). Its current U.S. Food and Drug Administration label covers CTCL in adults who have received at least one prior systemic therapy; the peripheral T-cell lymphoma use was removed from the label in 2021. Given on days 1, 8, and 15 of a 28-day cycle, it achieves response rates of approximately 34–38% in refractory CTCL, with particularly good responses in Sézary syndrome. Side effects include nausea, fatigue, QTc prolongation (cardiac rhythm monitoring required), and cytopenias. Infection risk is significant.

Mogamulizumab

Mogamulizumab is a humanized anti-CCR4 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). CCR4 (CC-chemokine receptor 4) is highly expressed on malignant MF and Sézary cells, making it an excellent therapeutic target. U.S. Food and Drug Administration-approved in 2018 for previously treated MF and Sézary syndrome, it demonstrated superior progression-free survival vs. vorinostat (7.7 months vs. 3.1 months) in the landmark MAVORIC trial (Kim et al., 2018). Important considerations:

Brentuximab Vedotin

Brentuximab vedotin is an antibody-drug conjugate: an antibody aimed at the CD30 marker, carrying a cell-killing drug. In the ALCANZA trial (Prince et al., 2017), 128 previously treated patients with CD30-positive cutaneous T-cell lymphoma (mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma) were analysed. A response lasting at least 4 months occurred in 56.3% with brentuximab vedotin, compared with 12.5% with the doctor's choice of methotrexate or bexarotene. Nerve damage (peripheral neuropathy) occurred in 67% of patients on brentuximab vedotin.

Denileukin Diftitox-cxdl

Denileukin diftitox-cxdl is a fusion protein made of diphtheria toxin fragments joined to human interleukin-2. Its U.S. Food and Drug Administration label covers adults with relapsed or refractory stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and carries a boxed warning for capillary leak syndrome, including life-threatening or fatal cases. In its phase III trial (Foss et al., 2025), 36.2% of 69 patients responded, including 8.7% with a complete response; the median response lasted 8.9 months. Capillary leak syndrome occurred in 20.3% (grade 3 or worse in 5.8%).

Extracorporeal Photopheresis (ECP)

ECP is a specialized immunotherapy procedure particularly effective for Sézary syndrome and erythrodermic MF. The process involves:

  1. Leukapheresis: white blood cells (mononuclear cells — MNCs) are separated from the patient's blood by an apheresis machine.
  2. Ex vivo photoactivation: the collected MNCs are exposed to 8-methoxypsoralen (8-MOP) and ultraviolet A irradiation outside the body (ex vivo).
  3. Reinfusion: the treated (partially killed/altered) cells are returned to the patient, where they appear to induce an immune response against the malignant T-cell clone.

ECP is typically performed on two consecutive days per month. It is well-tolerated with few systemic side effects. Response rates of 30–80% in erythrodermic CTCL are reported, with best responses in patients with lower Sézary cell burdens and shorter disease duration. ECP is frequently combined with other systemic agents (bexarotene, interferon-alpha) for enhanced response.

Allogeneic Stem Cell Transplantation (Allo-SCT)

Allo-SCT offers curative potential for advanced MF and Sézary syndrome, with sustained complete remissions reported in a subset of patients — likely driven by graft-versus-lymphoma (GVL) effect. However, it carries significant treatment-related mortality (TRM) from infection, GVHD, and organ toxicity, and is reserved for younger, fit patients with advanced refractory disease. Patient selection and timing matter: the mogamulizumab label reports more transplant complications when the drug was given within about 50 days before transplant.

Back to Table of Contents

Prognosis

Prognosis in MF is strongly determined by disease stage at diagnosis. The reassuring reality for most patients — who present with early patch or plaque disease — is that survival is not substantially different from age-matched controls when disease remains at stage IA.

Adverse prognostic factors beyond stage include: elevated lactate dehydrogenase, large-cell transformation, folliculotropic MF (a variant with follicular involvement that is more aggressive), and older age at diagnosis. Folliculotropic MF is staged and treated as if it were one stage higher than its skin involvement would suggest.

A 2010 study of 1,502 patients from one UK centre (Agar et al.) found that 71% presented at an early stage; the disease progressed in 34%, and 26% died of MF or Sézary syndrome. Independent markers of worse survival were advanced skin (T) stage, the tumor clone in the blood without Sézary cells, raised lactate dehydrogenase and the folliculotropic form.

Back to Table of Contents

Quality of Life and Patient Guidance

Living with MF presents unique challenges — the combination of a chronic, incurable (at early stage), visible skin disease with a cancer diagnosis creates significant psychological burden. Key considerations:

The Pruritus Problem

Pruritus (itch) is often the most debilitating symptom, frequently described by patients as "maddening" and far more distressing than the visible appearance of lesions. Scratching damages already fragile skin, creates entry points for infection, and disrupts sleep. Treatments targeting itch specifically — including antihistamines (limited efficacy), gabapentin, aprepitant (NK1 receptor antagonist), and dupilumab (in select cases) — may provide relief. Importantly, treating the underlying MF effectively is the most reliable way to control pruritus.

Psychosocial Burden

The combination of a cancer diagnosis, chronic visible skin changes, severe itch, and prolonged diagnostic uncertainty (many patients receive incorrect diagnoses for years before MF is confirmed) is associated with high rates of anxiety and depression. Peer support groups — particularly those specifically for CTCL/MF — can provide community, information, and emotional support that general cancer support groups may not offer. The Cutaneous Lymphoma Foundation (CLF) maintains patient education resources and a patient registry.

Infection Risk

Disrupted skin barrier and immunosuppressive treatments significantly increase infection risk. Staphylococcus aureus colonization of MF skin lesions is nearly universal and can trigger flares; many dermatologists incorporate skin decolonization protocols (dilute bleach baths, mupirocin nasal ointment) into routine management. Increased warmth, pain, pus (purulent discharge) and fever are signs of skin infection, which is treated early.

Questions Patients Often Raise With Their Dermatologist

Clinical Trials

Given the rarity of MF and the limited curative options available outside of allogeneic transplant, clinical trials are one of the routes to newer treatments for advanced or refractory disease. Active trials can be identified at clinicaltrials.gov by searching "mycosis fungoides" or "cutaneous T-cell lymphoma."

Back to Table of Contents

Key Research Papers

  1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354–371. — PubMed PMID: 9207472
  2. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722. — PubMed PMID: 17540844
  3. Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. — PubMed PMID: 34446710
  4. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. — PubMed PMID: 30100375
  5. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115. — PubMed PMID: 17577020
  6. Piekarz RL, Frye AR, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417. — PubMed PMID: 19826128
  7. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141(3):305–311. — PubMed PMID: 15781671
  8. Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. — PubMed PMID: 24354653
  9. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491. — PubMed PMID: 20697094
  10. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. — PubMed PMID: 16960145
  11. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. — PubMed PMID: 15692063
  12. Jahan-Tigh RR, Ryan C, Obermoser G, Schwarzenberger K. Flow cytometry. J Invest Dermatol. 2012;132(10):1–6. — PubMed PMID: 22971922
  13. Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32. — PubMed PMID: 23069814
  14. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566. — PubMed PMID: 28600132
  15. Foss FM, Kim YH, Prince HM, et al. Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2025;43(10):1198–1209. — PubMed PMID: 39700456
  16. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739. — PubMed PMID: 20855822

Search PubMed for more: Mycosis fungoides treatment Cutaneous T-cell lymphoma CTCL Sézary syndrome

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents